Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells

著者: Barbara Withers, Emily Blyth, Leighton Clancy, Agnes S. M. Yong, Chris Fraser, Jane Burgess, Renee Simms, Rebecca T. Brown, David Kliman, Ming‐Celine Dubosq, David Bishop, Gaurav Sutrave, Chun Kei Kris, Peter J. Shaw, Kenneth Micklethwaite, David Gottlieb - Blood Advances 2017 被引用: 141

Key Points Partially HLA-matched third-party CMV-specific T cells provide long-term viral control in HSCT patients with resistant CMV infection. Viral control occurs in the setting of recovery of CD8+ terminally differentiated effector T cells.